Nautilus Biotechnology (NASDAQ:NAUT) Shares Up 0.8% – What’s Next?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT)’s share price rose 0.8% on Friday . The stock traded as high as $2.50 and last traded at $2.40. Approximately 108,352 shares were traded during mid-day trading, an increase of 37% from the average daily volume of 79,021 shares. The stock had previously closed at $2.38.

Nautilus Biotechnology Stock Performance

The business has a 50-day moving average of $2.70 and a 200-day moving average of $2.61. The stock has a market capitalization of $301.35 million, a price-to-earnings ratio of -4.29 and a beta of 1.23.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04. During the same period last year, the company earned ($0.13) earnings per share. On average, research analysts predict that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Mary E. Godwin sold 35,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $2.85, for a total transaction of $99,750.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 40.50% of the company’s stock.

Institutional Trading of Nautilus Biotechnology

A number of institutional investors have recently added to or reduced their stakes in NAUT. Price T Rowe Associates Inc. MD increased its holdings in Nautilus Biotechnology by 35.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock valued at $48,000 after buying an additional 4,239 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Nautilus Biotechnology by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock valued at $69,000 after purchasing an additional 9,404 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Nautilus Biotechnology by 11.2% during the second quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock worth $328,000 after purchasing an additional 14,100 shares during the last quarter. Clarius Group LLC raised its holdings in Nautilus Biotechnology by 2.7% during the second quarter. Clarius Group LLC now owns 636,532 shares of the company’s stock worth $1,489,000 after purchasing an additional 16,661 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Nautilus Biotechnology during the third quarter worth $50,000. Hedge funds and other institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.